SRI-29329 manufacturers
- SRI-29329
-
- $50.00
-
2026-07-27
- CAS:2086809-58-5
- Purity: 99.49%
- Supply Ability: 10g
|
| | SRI-29329 Basic information |
| Product Name: | SRI-29329 | | Synonyms: | SRI-29329;9H-Purine-2,6-diamine, N2-[(1S,2S)-2-aminocyclohexyl]-N6-(3-chlorophenyl)-9-(1-methylethyl)-;Cyclin dependent kinase,inhibit,SRI29329,SRI-29329,Inhibitor,SRI 29329,CDK;SRI-29329, 10 mM in DMSO;N2-((1S,2S)-2-Aminocyclohexyl)-N6-(3-chlorophenyl)-9-isopropyl-9H-purine-2,6-diamine | | CAS: | 2086809-58-5 | | MF: | C20H26ClN7 | | MW: | 399.92 | | EINECS: | | | Product Categories: | | | Mol File: | 2086809-58-5.mol |  |
| | SRI-29329 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : 50 mg/mL (125.03 mM; Need ultrasonic) | | form | Solid | | color | White to off-white |
| | SRI-29329 Usage And Synthesis |
| Uses | SRI-29329 is a specific CLK inhibitor, with IC50 values of 78 nM, 16 nM and 86 nM for CLK1, CLK2 and CLK4, respectively[1]. | | Biological Activity | SRI-29329 is a specific CLK inhibitor, with IC50 values of 78 nM, 16 nM and 86 nM for CLK1, CLK2 and CLK4, respectively[1].
SRI-29329 (compound 8) shows some modest (~5 fold) selectivity for CLK2 over CLK1 and CLK4 without significant CDK1,4,6 activity[1]. | | References | [1]. Yihui Shi, et al. A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore. Bioorg Med Chem Lett. 2017 Feb 1;27(3):406-412. |
| | SRI-29329 Preparation Products And Raw materials |
|